FindTrial
Sign In

Research of radical treatment regimen for P. vivax malaria

Research of risk factors for malaria infection and radical treatment regimen along cross China-Myanmar border

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012523
Enrollment
Unknown
Registered
2017-08-31
Start date
2017-10-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malaria

Interventions

Group of artemisinin-naphthoquine combination plus primaquine:artemisinin-naphthoquine combination plus primaquine
Group of chloroquine-primaquine:chloroquine-primaquine

Sponsors

Yunnan Institute of Parasitic Diseases
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Microscopy- confirmed patients with monoinfections of P. vivax; 2. Aged 1–65 years; 3. Asexual parasite density =500 parasites/ul.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Having taken any anti-malarial drug within the past 14 days; 3. History of hypersensitivity to any of the study drugs; 4. Severe dysfunction of kidney, liver and heart; 5. Severe malaria such as cerebral malaria, hyper body temperature (>41 degree C); 6. Unable to follow up.

Design outcomes

Primary

MeasureTime frame
radical rate after one year;Parasite clearance times;—

Secondary

MeasureTime frame
Fever clearance times;—

Countries

Myanmar

Contacts

Public ContactHui LIU

Yunnan Institute of Parasitic Diseases

liubible@126.com+86 15308796079

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026